Prostaglandins are approved by the European Glaucoma Society guidelines as first-line
treatment for glaucoma. This review focuses on latanoprost, an ester prodrug of …

Dry eye disease (DED) is a multifactorial disease that represents one of the most common
ophthalmologic conditions encountered in everyday clinical practice. Traditional diagnostic …

Introduction Latanoprostene bunod (LBN) is a novel nitric oxide (NO)-donating
prostaglandin F2α analog. We evaluated the long-term safety and intraocular pressure (IOP) …

Glaucoma is a chronic, debilitating disease and a leading cause of global blindness.
Despite treatment efforts, 10% of patients demonstrate loss of vision. In the US,> 80% of …

Objective: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of
the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and …

Glaucoma is the second most common cause of world blindness (following cataract) with
estimated cases reaching 79.6 million by 2020. Although the etiology of glaucoma is multi …

The aim of this study was to examine whether the antioxidant epigallocatechin gallate
(EGCG), a catechin-base flavonoid derived from green tea protects retina neurones in situ …

Highlights•Drug injection into the suprachoroidal space using microneedles offers direct
access to the choroid and retina.•It is a promising alternative to intravitreal injection.•Benefits …

The purpose of the present study was to determine whether the flavonoid, baicalin is
effective at blunting the negative influence of ischemia/reperfusion to the rat retina in situ …

Glaucoma is a slow progressive degeneration of the retinal ganglion cells (RGCs) and the
optic nerve axons, leading to irreversible blindness if left undiagnosed and untreated …